Current Role of Melanocortin in Erectile Dysfunction

Caesar Alaienia Pharm.D. • Sadaf Jalili B.S. • S. Ali Khan M.D. • Jeannene Strianse RPh., M.S. • Edmund Hayes RPh, M.S., Pharm.D.
Department of Pharmacy and Urology, Stony Brook University Medical Center, New York.

Introduction

The 5 phases of male sexual function includes, libido, penile erection, ejaculation, orgasm and detumescence. In patients with erectile dysfunction peripherally acting phosphodiesterase 5 (pde-5) inhibitors are useful to improve erectile dysfunction. A new pharmacologic agent, Melanocortin is a centrally acting agent that improves penile erection. Melanocortin primarily acts on MC3 and MC4 receptors in the hypothalamus. MC4 receptors are emerging as the main mediators of penile erection. Currently there are several directly acting melanocorticnergic agents that include PP-228, THIQ, and bremenlotide (PT-141). This poster will review the current pharmacological role of melanocortin in penile erection.

Methods

A review of recent literature data from various medical search engines was analyzed to determine the current pharmacology of melanocortin in human and animal research subjects. Role of melanocortin related to penile erection is discussed. Search terms used were melanocortin, erectile dysfunction and male sexual dysfunction. Gene manipulation in animal models to remove MC3 receptors was also studied.

Results

Data from the search engines reveals that Melanocortin may be a useful agent in patients with erectile dysfunction secondary to underlying co morbidities. Data from phase II clinical trials of bremenlotide supports the use of melanocortin-based therapy in patients with erectile dysfunction. Melanocortin may also improve sexual desire and arousal in women.

Conclusion

Currently the first line oral treatment options for erectile dysfunction are the peripherally acting pde-5 inhibitors. Patients who have failed pde-5 medications or have contraindications may soon have another option. In patients who use pde-5 inhibitors to improve erectile dysfunction and develop hypotension, melanocortin may be an alternative to overcome this serious side effect especially in patients who are contraindicated because of concurrent use of nitrates or nitric oxide donors. Stimulation of the melanocortin system has shown to be effective to treat erectile dysfunction. Further studies are needed to study the pharmacodynamics of melanocortin in human subjects.

References: